Maxcyte, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+9.45%
vs ±81.8% implied · ×0.12
shaded = implied · ▲▼ = realized
Maxcyte has 1 disclosed supplier and 4 disclosed customers in SEC filings.
Maxcyte, Inc.
1.57
SentenceIn January 2025, we acquired SeQure Dx, ("SeQure") a market leader for on-target and off-target editing assessment services for cell and gene therapies.
MXCT 10-Kaccession 0001104659-26-034557
SentenceAlthough Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.
SentenceAlthough Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.
SentenceAlthough Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.
MXCT 10-Kaccession 0001104659-26-034557
SentenceFrom leading commercial cell therapy drug and biologic developers and top biopharmaceutical companies to top academic and government research institutions, including the NIH, our customers have extensively validated our technology.
MXCT 10-Kaccession 0001104659-26-034557
Linked news
NewsExpected move
No implied move.